134 related articles for article (PubMed ID: 1320606)
1. Effect of pH on antibiotics used to treat anaerobic infection.
Winstanley TG; Wilcox MH; Spencer RC
J Antimicrob Chemother; 1992 May; 29(5):594-5. PubMed ID: 1320606
[No Abstract] [Full Text] [Related]
2. Susceptibilities of 428 gram-positive and -negative anaerobic bacteria to Bay y3118 compared with their susceptibilities to ciprofloxacin, clindamycin, metronidazole, piperacillin, piperacillin-tazobactam, and cefoxitin.
Pankuch GA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1993 Aug; 37(8):1649-54. PubMed ID: 8215278
[TBL] [Abstract][Full Text] [Related]
3. Comparative in vitro activities of a new quinolone, WIN 57273, and piperacillin plus tazobactam against anaerobic bacteria.
Venezia RA; Yocum DM; Robbiano EM; Echols RM
Antimicrob Agents Chemother; 1990 Sep; 34(9):1858-61. PubMed ID: 2178340
[TBL] [Abstract][Full Text] [Related]
4. The sensitivity of clinical isolates of anaerobic species to piperacillin-tazobactam and other antimicrobial agents.
Namavar F; Severin WP; Stobberingh E; Smeets T; MacLaren DM
J Antimicrob Chemother; 1994 Sep; 34(3):415-9. PubMed ID: 7829416
[No Abstract] [Full Text] [Related]
5. In vitro activities of clindamycin, imipenem, metronidazole, and piperacillin-tazobactam against susceptible and resistant isolates of Bacteroides fragilis evaluated by kill kinetics.
Schaumann R; Funke M; Janssen E; Rodloff AC
Antimicrob Agents Chemother; 2012 Jun; 56(6):3413-6. PubMed ID: 22430962
[TBL] [Abstract][Full Text] [Related]
6. Comparative in vitro antimicrobial activity of a novel quinolone, garenoxacin, against aerobic and anaerobic microbial isolates recovered from general, vascular, cardiothoracic and otolaryngologic surgical patients.
Edmiston CE; Krepel CJ; Kehl KS; Seabrook GR; Somberg LB; Almassi GH; Smith TL; Loehrl TA; Brown KR; Lewis BD; Towne JB
J Antimicrob Chemother; 2005 Nov; 56(5):872-8. PubMed ID: 16186167
[TBL] [Abstract][Full Text] [Related]
7. Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes.
Spangler SK; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1994 Oct; 38(10):2471-6. PubMed ID: 7840591
[TBL] [Abstract][Full Text] [Related]
8. Effect of pH on in vitro antimicrobial susceptibility of the Bacteroides fragilis group.
Falagas ME; McDermott L; Snydman DR
Antimicrob Agents Chemother; 1997 Sep; 41(9):2047-9. PubMed ID: 9303414
[TBL] [Abstract][Full Text] [Related]
9. Susceptibility of anaerobic bacteria to the new streptogramin RP 59500 in vitro.
Nord CE; Lindmark A; Persson I
Eur J Clin Microbiol Infect Dis; 1989 Dec; 8(12):1064-7. PubMed ID: 2559846
[TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics and antimicrobial susceptibilities of anaerobic bacteremia in an acute care hospital.
Tan TY; Ng LS; Kwang LL; Rao S; Eng LC
Anaerobe; 2017 Feb; 43():69-74. PubMed ID: 27890724
[TBL] [Abstract][Full Text] [Related]
11. Resistance trends of Bacteroides fragilis group over an 8-year period, 1997-2004, in Korea.
Roh KH; Kim S; Kim CK; Yum JH; Kim MS; Yong D; Lee K; Kim JM; Chong Y
Korean J Lab Med; 2009 Aug; 29(4):293-8. PubMed ID: 19726890
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of quinolones and other antimicrobial agents against anaerobic bacteria.
Nord CE
Clin Infect Dis; 1996 Dec; 23 Suppl 1():S15-8. PubMed ID: 8953101
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of ceftriaxone combined with tazobactam against anaerobic bacteria.
Wüst J; Hardegger U
Eur J Clin Microbiol Infect Dis; 1994 Feb; 13(2):177-81. PubMed ID: 8013494
[TBL] [Abstract][Full Text] [Related]
14. Susceptibility of anaerobic bacteria from several French hospitals to three major antibiotics.
Dubreuil L; Devos J; Neut C; Romond C
Antimicrob Agents Chemother; 1984 Jun; 25(6):764-6. PubMed ID: 6742819
[TBL] [Abstract][Full Text] [Related]
15. [Comparative activity of 9 beta-lactamines, clindamycin and metronidazole on strictly anaerobic bacteria].
Derriennic M; Reynaud A; Launay C; Courtieu AL
Pathol Biol (Paris); 1987 May; 35(5):572-6. PubMed ID: 3302862
[TBL] [Abstract][Full Text] [Related]
16. Susceptibility of anaerobic bacteria to FCE 22101.
Nord CE; Lindmark A; Person I
Antimicrob Agents Chemother; 1987 May; 31(5):831-3. PubMed ID: 3038012
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of piperacillin/tazobactam in the treatment of experimental intra-abdominal infections.
Nord CE; Lahnborg G
Eur J Surg Suppl; 1994; (573):45-9. PubMed ID: 7524795
[TBL] [Abstract][Full Text] [Related]
18. [Use of the Etest method for antimicrobial susceptibility testing of obligate anaerobes].
Rokosz A; Sawicka-Grzelak A; Kot K; Meszaros J; Łuczak M
Med Dosw Mikrobiol; 2001; 53(2):167-75. PubMed ID: 11757426
[TBL] [Abstract][Full Text] [Related]
19. Susceptibility of anaerobes in phase 3 clinical studies of piperacillin/tazobactam.
Jacobus NV; Immermann FW; Gupte JM; Testa RT
Clin Infect Dis; 1993 Jun; 16 Suppl 4():S344-8. PubMed ID: 8391862
[No Abstract] [Full Text] [Related]
20. Anaerobic cocci and their resistance patterns to penicillin, cefoxitin, clindamycin and metronidazole: a Bulgarian study.
Boyanova L; Osmanliev D; Petrov D; Mitov I; Usunova I; Petrov S; Minchev TZ
Clin Microbiol Infect; 2000 Nov; 6(11):623-4. PubMed ID: 11168069
[No Abstract] [Full Text] [Related]
[Next] [New Search]
